Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2017-03-16
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The major objectives of the BHAS Study are to (1) establish a prospective cohort and a biological sample bank in ethnic Chinese with coronary angiography, (2) identify baseline new biosignature profiles such as novel biomarkers via metabolomics approach associated with the subsequent clinical events, (3) assess the use of molecular profiles from multiple platforms (eg, genomics, proteomics, and metabolomics) integrated with readily available clinical information for improved risk classification for cardiovascular events, and (4) provide clearer understanding of underlying disease processes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Screening and Identification for Panvascular Diseases
NCT05485870
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
NCT06793774
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV
NCT06793787
Study on the Accuracy of Determining the Responsible Vessel in Medium Vessel Occlusive Stroke Based on Multi-type CT Evaluation
NCT07347587
A Prospective Multicenter Clinical Study on the Long-term Prognosis of Patients With ST-segment Elevation Myocardial Infarction Using Cardiac Magnetic Resonance Imaging.
NCT07057492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Consent for the study
* Primary reason for catheterization is concern for ischemic heart disease
* Complete clinical and coronary angiogram data available
Exclusion Criteria
* Cardiac transplantation
* Other solid organ transplant
* Peripheral vascular intervention only
* Right heart catheterization only
* Advanced heart failure
* Congenital heart disease
* Women who are pregnant or nursing, or preparing for pregnant during the study period
* Progressive fatal disease
* History of alcoholism or drug abuse
* Patients with mental illness and are being treated
* Patients are undergoing radiotherapy or chemotherapy
* Acute and chronic infectious diseases
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fusui Ji, MD
Director, Department of Gerontological Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fusui Ji, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology, Beijing Hospital,National Center of Gerontology
Wenxiang Chen, M.D.
Role: PRINCIPAL_INVESTIGATOR
The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology
Xue Yu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology, Beijing Hospital,National Center of Gerontology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bejing Hosptial
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008 Feb 19;51(7):701-7. doi: 10.1016/j.jacc.2007.10.034.
Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. J Am Coll Cardiol. 2016 Dec 27;68(25):2850-2870. doi: 10.1016/j.jacc.2016.09.972.
Wang Y, Yang R, Zhang Y, Wang Z, Wang X, Wang S, Zhang W, Yu X, Dong J, Chen W, Ji F. Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction. Rev Cardiovasc Med. 2022 Dec 2;23(12):394. doi: 10.31083/j.rcm2312394. eCollection 2022 Dec.
Yang R, Zhang W, Wang X, Wang S, Zhou Q, Li H, Mu H, Yu X, Ji F, Dong J, Chen W. Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography. Front Endocrinol (Lausanne). 2022 Sep 5;13:978520. doi: 10.3389/fendo.2022.978520. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016BJYYEC-121-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.